Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in...
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing...